research Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction.
5α-reductase inhibitors may worsen sexual drive and spontaneous erections but don't worsen existing erectile or ejaculatory problems.
Search
for
Sort by
Research
150-180 / 1000+ results 
research LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
research Hormonal Control of Cardiac Action Potential Phase 1 Currents in the Brugada Syndrome
Androgens may increase arrhythmias in Brugada Syndrome, while Finasteride could reduce them.
research Pharmacological Role and Clinical Applications of 5α-Reductase Inhibitors-Review Article for Pharmacists and Healthcare Professionals
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
research Design, synthesis and structure-activity relationships studies on steroidal aromatase and 5α-reductase inhibitors as anti-tumors
Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
research Adrenolytic and Vasodilator Therapy
New drugs like clonidine and prazosin show promise for treating high blood pressure despite some side effects.
research The effects of finasteride (FIN) and thioacetamide (TAA) on acetylcholinesterase (AchE) activity in various brain regions.
research Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis
Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
research (379) The Effect of 5-α Reductase Inhibitor on Male Reproductive Function
5-α reductase inhibitors do not significantly affect male reproductive function but may reduce semen volume.
research Modulation of the 6-position of benzopyran derivatives and inhibitory effects on the insulin releasing process
Changing the 6-position on benzopyran molecules affects insulin release, with some compounds showing strong inhibitory effects.
research QSAR Analysis of a Series of Hydantoin‐based Androgen Receptor Modulators and Corresponding Binding Affinities
Researchers developed reliable models to predict how well certain compounds bind to androgen receptors, emphasizing the importance of atomic electronegativity.
research Towards the Development of AgoKirs: New Pharmacological Activators to Study Kir2.x Channel and Target Cardiac Disease
New compounds may help treat heart disease by activating specific potassium channels.
research Dutasteride, a novel dual 5-A reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients
Dutasteride reduces DHT more effectively than finasteride.
research 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice
5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
research Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: From potassium channel openers to calcium entry blockers?
New compounds similar to cromakalim were less effective at inhibiting insulin release but improved in solubility and one acted as a calcium entry blocker, not a potassium channel opener.
research Is sulfonamide group of tamsulosin main factor in the pathophysiology of floppy iris syndrome?
Tamsulosin's sulfonamide group may contribute to floppy iris syndrome.
research Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductase
Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
research Novel inhibitors of 5α-reductase
New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
research Abstract A12: Androgen receptor inhibition is involved in Finasteride-reduced AML cell proliferation
Finasteride reduces AML cell growth by inhibiting androgen receptors.
research When two plus two must not equal four
Regulatory challenges make developing combination therapies in urology difficult and costly.
research Dutasteride/finasteride
research FRI-02 FROM GIRLS TO BOYS TO OLDER MEN, THE INTERESTING TALE OF THE GUEVEDOCES AND 5-ALPHA REDUCTASE INHIBITORS
The discovery of 5α-reductase deficiency in guevedoces led to the development of important urologic medications.
research Determination of rat 5α-reductase type 1 isozyme activity and its inhibition by novel steroidal oxazolines
New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
research 2-Substituted 4-(Thio)chromenone 6-O-Sulfamates: Potent Inhibitors of Human Steroid Sulfatase
New compounds were made that block an enzyme linked to breast cancer better than existing treatments.
research Identification of Anabolic Selective Androgen Receptor Modulators with Reduced Activities in Reproductive Tissues and Sebaceous Glands
Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.
research MP45-10 HISTOMORPHOMETRICAL EVALUATION OF THE CORPUS CAVERNOSUM OF HYPERTENSIVE RATS TREATED WITH 5-?-REDUCTASE INHIBITORS
SHH protein helps nerve regeneration in hypertensive rats.
research 1116 Novel androgen receptor degrader for androgenetic alopecia (AGA) application
A new treatment for hair loss shows promise with fewer side effects.
research 5alpha-reductase: history and clinical importance.
5alpha-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT, offering symptom relief and potential future uses.
research Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial
The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.